Personalis, Inc.
Close on Oct 19, 2026
- Market cap
- $1.67B
- P/E (TTM)
- –
- Dividend yield
- –
About Personalis
Services-Medical Laboratories, SIC 8071
Personalis, Inc. operates as a cancer genomics company focused on enabling personalized cancer therapies and providing diagnostic testing solutions. The company offers specialized laboratory testing services that support clinical diagnostics and pharmaceutical research and development, including population sequencing and enterprise sales. Its service offerings assist biopharmaceutical and clinical diagnostic partners in advancing cancer therapeutics, monitoring disease progression, and supporting clinical trials. Key customers include biopharmaceutical organizations such as Moderna, Pfizer, and Merck, along with healthcare entities like AstraZeneca and government initiatives such as the U.S. Department of Veterans Affairs' Million Veteran Program.
The company operates primarily through a single consolidated headquarters and laboratory facility located in the United States, alongside an international presence via its subsidiary in the United Kingdom. Operations, sales, and research activities are supported through domestic facilities and commercial partnerships spanning global jurisdictions. Personalis maintains its corporate headquarters and primary laboratory operations in Fremont, California.
Summary of the business section of Personalis's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Personalis, Inc.
- Founded
- 2011
- Headquarters
- Fremont, CA
- Address
- 6600 Dumbarton Circle 94555
- Phone
- (650) 752-1300
- Website
- personalis.com
- Employees
- 260, Dec 31, 2025
- Industry
- Services-Medical Laboratories
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BDO USA, P.C., San Jose, California
Stock & identifiers
- Ticker
- PSNL
- Exchange
- Nasdaq
- IPO date
- Jun 20, 2019
- Shares outstanding
- 107M, Jul 29, 2026
- Public float
- $578.18M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1527753
- CUSIP
- 71535D106
- ISIN
- US71535D1063
- LEI
- 549300EZ2NYFK7H0US48
- EIN
- 27-5411038
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Christopher M. Hall | Chief Executive Officer, Director | 228,527 |
| Richard Chen | President and CMO | 169,882 |
| Stephen Michael Moore | SVP and Chief Legal Officer | 90,257 |
| Aaron Tachibana | CFO AND COO | 195,902 |
| Karin Eastham | Director | 19,756 |
| Lonnie Shoff | Director | 37,190 |
| A. Blaine Bowman | Director | 19,756 |
| Olivia Kyusuk Bloom | Director | 27,265 |
| Woodrow A. Myers Jr | Director | 32,366 |
| Kenneth J. Widder | Director | 6,250 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Christopher Hall | $3.51M | $7.60M | $1.60M | $402 | – |
| FY2024 Christopher Hall | $1.54M | $4.41M | $1.00M | $292 | – |
| FY2023 Aaron Tachibana | $1.67M | $1.40M | $975.89K | $106 | – |
| FY2023 Christopher Hall | $1.73M | $1.40M | $975.89K | $106 | – |
| FY2022 Aaron Tachibana | $676.01K | -$2.21M | $951.54K | $14 | – |
| FY2022 John West | $5.62M | -$2.30M | $951.54K | $14 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of January 31, 2026, we had 260 employees, of which 259 were full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 9, 2023 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jun 20, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 17, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |